LEADER 05531nam 2201309z- 450 001 9910566462603321 005 20220506 035 $a(CKB)5680000000037755 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81051 035 $a(oapen)doab81051 035 $a(EXLCZ)995680000000037755 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aRegional Intestinal Drug Absorption$eBiopharmaceutics and Drug Formulation 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (238 p.) 311 08$a3-0365-3658-2 311 08$a3-0365-3657-4 330 $aThe gastrointestinal tract (GIT) can be broadly divided into several regions: the stomach, the small intestine (which is subdivided to duodenum, jejunum, and ileum), and the colon. The conditions and environment in each of these segments, and even within the segment, are dependent on many factors, e.g., the surrounding pH, fluid composition, transporters expression, metabolic enzymes activity, tight junction resistance, different morphology along the GIT, variable intestinal mucosal cell differentiation, changes in drug concentration (in cases of carrier-mediated transport), thickness and types of mucus, and resident microflora. Each of these variables, alone or in combination with others, can fundamentally alter the solubility/dissolution, the intestinal permeability, and the overall absorption of various drugs. This is the underlying mechanistic basis of regional-dependent intestinal drug absorption, which has led to many attempts to deliver drugs to specific regions throughout the GIT, aiming to optimize drug absorption, bioavailability, pharmacokinetics, and/or pharmacodynamics. In the book "Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation" we aim to highlight the current progress and to provide an overview of the latest developments in the field of regional-dependent intestinal drug absorption and delivery, as well as pointing out the unmet needs of the field. 517 $aRegional Intestinal Drug Absorption 606 $aManufacturing industries$2bicssc 606 $aMedicine and Nursing$2bicssc 610 $aabsorption-modifying excipients 610 $aBCS class IV drugs 610 $aBCS drugs 610 $abioequivalence 610 $abiomimetic membrane 610 $abiopharmaceutics 610 $abiopharmaceutics classification system 610 $aBiopharmaceutics Classification System 610 $aclinical studies 610 $acolon absorption 610 $acombined zero- and first-order absorption 610 $acontrolled release drug product 610 $aDDI 610 $adisintegration 610 $adissolution 610 $adissolution test 610 $adrug absorption 610 $adrug permeability 610 $adrug solubility 610 $adrug solubility/dissolution 610 $adrug-drug interactions 610 $aenergy intake 610 $aenteric-coated 610 $afirst-order absorption 610 $afirst-pass effect 610 $aFranz cell 610 $aFranz-PAMPA 610 $afurosemide 610 $agastrointestinal 610 $agastrointestinal hormone 610 $aGastroPlus 610 $ahierarchical support vector regression (HSVR) 610 $ahuman colon carcinoma cell layer (Caco-2) 610 $aibuprofen 610 $aICH 610 $ain silico modeling 610 $ain situ perfusion 610 $ain vitro 610 $ain vitro in vivo extrapolations 610 $aintestinal absorption 610 $aintestinal perfusion 610 $aintestinal permeability 610 $aIVIVE 610 $alocation-dependent absorption 610 $amanometry 610 $amechanistic modeling 610 $amicrodevices 610 $amucoadhesion 610 $anutrient absorption 610 $anutrient digestion 610 $aobesity 610 $aoral absorption 610 $aoral drug delivery 610 $aoral peptide delivery 610 $apassive drug transport 610 $aPBBM 610 $aPBPK 610 $apermeation enhancers 610 $apharmaceutical development 610 $apharmacokinetics 610 $aPhoenix WinNonlin 610 $aphysiologically-based pharmacokinetic (PBPK) modeling 610 $apostprandial glycaemia 610 $apravastatin 610 $aquality control 610 $aregion of the gut 610 $aregional intestinal permeability 610 $aregional/segmental-dependent permeability and absorption 610 $aroute-dependent intestinal metabolism 610 $asegmental-dependent intestinal permeability 610 $asegregated flow intestinal model (SFM) 610 $ashape 610 $atraditional model (TM) 610 $atransit compartment absorption model 610 $atype 2 diabetes 610 $azero-order absorption 615 7$aManufacturing industries 615 7$aMedicine and Nursing 700 $aGonzalez-Alvarez$b Maria Isabel$4edt$01330868 702 $aDahan$b Arik$4edt 702 $aGonzalez-Alvarez$b Maria Isabel$4oth 702 $aDahan$b Arik$4oth 906 $aBOOK 912 $a9910566462603321 996 $aRegional Intestinal Drug Absorption$93040001 997 $aUNINA